As of this week, the following products manufactured from expanded cord blood have been granted expedited pathways to FDA approval.
Parent's Guide to Cord Blood Foundation published a review of expanded cord blood products in May 2018.
| Date | Expanded Cord Blood Product | Manufacturer | Indication | FDA Expedited Path(s) |
| 20180717 | NiCord® | Gamida Cell | HSCT: Hematopoietic Stem Cell Transplants | Breakthrough Therapy Orphan Drug |
| 20180806 | NLA101 Dilanubicel | Nohla Therapeutics | HSCT engraftment, Neutropenia | Orphan Drug Fast Track |
| 20180823 | Pneumostem® | Medipost | Bronchopulmonary Dysplasia | Orphan Drug Fast Track |
| 20190423 | ECT-001 | ExCellThera | Hematologic Malignancies | Regenerative Medicine Advanced Therapy (RMAT) |
| 20190904 | MGTA-456 | Magenta Therapeutics | Inherited Metabolic Disorders | Regenerative Medicine Advanced Therapy (RMAT) |
Comments Disclaimer
These comments are submitted by website readers and are not endorsed by CellTrials.org, which is a project of Parent's Guide to Cord Blood Foundation. We screen the comments to keep out SPAM but we cannot review each one for accuracy.